Press Release – RepliCel Provides Quarterly Update

Snippet from the press release:

RepliCel Life Sciences Inc. is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.

To date, 17 of 19 subjects have had their six-month follow-up visit, during which time subjects had their overall health evaluated. This included subjective and objective assessment of verum and placebo injected sites and digital images were taken of the scalp and injection areas.

Read the full text — RepliCel Provides Quarterly Update on First-In-Man Clinical Trials